Teva, Viatris win new chance to challenge J&J schizophrenia drug patent | Business Information & News | Westlaw

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent | Business Information & News | Westlaw

View on Westlaw or start a FREE TRIAL today, Teva, Viatris win new chance to challenge J&J schizophrenia drug patent, Business Information & News
4/1/24 REUTERS LEGAL 15:52:58
REUTERS LEGAL
Copyright (c) 2024 Thomson Reuters
April 1, 2024
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Blake Brittain
Bill Berkrot
Blake Brittain; Washington
Alexia Garamfalvi
(Reuters) -Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic...
---- Index References ----
Company: VIATRIS INC.; TEVA PHARMACEUTICAL INDUSTRIES LIMITED
News Subject: (Intellectual Property (1IN75); Legal (1LE33); Patents (1PA79))
Industry: (Generic Drugs (1GE93); Healthcare (1HE06); Healthcare Practice Specialties (1HE49); Healthcare Services (1HE13); Pharmaceutical Patents (1PH40); Pharmaceuticals (1PH33); Pharmaceuticals & Biotechnology (1PH13); Psychiatric Disorders & Conditions (1PS79); Psychiatric Services (1PS61); Psychiatry (1PS63); Schizophrenia (1SC28))
Region: (Americas (1AM92); New Jersey (1NE70); North America (1NO39); U.S. Mid-Atlantic Region (1MI18); USA (1US73))
Language: EN
Other Indexing: (J&J; Viatris; Teva Pharmaceutical)
Keywords: ip; ip; health; Appellate
Word Count: 301
End of Document© 2024 Thomson Reuters. No claim to original U.S. Government Works.